Investment Thesis
Assembly Biosciences demonstrates strong revenue growth (+153.5% YoY) but is burning significant cash with negative operating income, negative free cash flow of -$41.2M, and deteriorating profitability metrics. Despite a solid balance sheet with $58.5M in cash and low debt, the company's current cash burn rate is unsustainable and threatens long-term viability without achieving profitability or securing additional funding.
Strengths
- Exceptional revenue growth of 153.5% year-over-year indicates strong commercial traction or successful product launches
- Strong balance sheet with $58.5M in cash, $206.8M stockholders' equity, and minimal debt (0.00x debt-to-equity ratio)
- High liquidity with current ratio of 5.22x provides runway to weather operational challenges
Risks
- Severe cash burn of -$41.1M in operating cash flow with negative free cash flow margin of -56.9%, indicating revenue growth is not translating to profitability
- Operating margin of -16.8% and net margin of -8.5% show the company is not yet profitable despite substantial revenue, suggesting unsustainable cost structure
- Continued negative operating cash flow at current burn rate would exhaust cash reserves within approximately 1.4 years without achieving profitability or securing additional capital
Key Metrics to Watch
- Path to operating profitability and operating margin expansion
- Operating cash flow trend and time to cash flow breakeven
- Cash burn rate and runway remaining at current burn levels
- Gross margin sustainability as revenue scales
Financial Metrics
Revenue
72.3M
Net Income
-6.1M
EPS (Diluted)
$-0.55
Free Cash Flow
-41.2M
Total Assets
257.6M
Cash
58.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-16.8%
Net Margin
-8.5%
ROE
-3.0%
ROA
-2.4%
FCF Margin
-56.9%
Balance Sheet & Liquidity
Current Ratio
5.22x
Quick Ratio
5.22x
Debt/Equity
0.00x
Debt/Assets
19.7%
Interest Coverage
-0.87x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T06:02:11.279881 |
Data as of: 2025-12-31 |
Powered by Claude AI